Moexipril patient counseling information: Difference between revisions
Amr Marawan (talk | contribs) No edit summary |
Amr Marawan (talk | contribs) No edit summary |
||
Line 29: | Line 29: | ||
====Pregnancy==== | ====Pregnancy==== | ||
Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors and should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. Patients should be asked to report pregnancies to their physicians as soon as possible.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE | Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors and should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. Patients should be asked to report pregnancies to their physicians as soon as possible.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 20:57, 14 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Moexipril
Moexipril and Hydrochlorothiazide tablet
Overview
Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [4]; Associate Editor(s)-in-Chief: Amr Marawan, M.D. [5]
Information for Patients
Food
Patients should be advised to take Moexipril HCl and Hydrochlorothiazide Tablets one hour before a meal.
Angioedema
Angioedema, including laryngeal edema, may occur with treatment with ACE inhibitors, usually occurring early in therapy (within the first month). Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of the face, extremities, eyes, lips, tongue, difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.
Symptomatic Hypotension
Patients should be cautioned that lightheadedness can occur with Moexipril HCl and Hydrochlorothiazide Tablets, especially during the first few days of therapy. If fainting occurs, the patient should stop taking Moexipril HCl and Hydrochlorothiazide Tablets and consult the prescribing physician.
All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult their physician if they develop these conditions.
Hyperkalemia
Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting their physician.
Neutropenia
Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) that could be a sign of neutropenia.
Pregnancy
Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors and should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. Patients should be asked to report pregnancies to their physicians as soon as possible.[1]
References
Adapted from the FDA Package Insert.